Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology
Glucotrack (NASDAQ:GCTK) has appointed Dr. David S. Hirsh as Medical Director of Cardiology to support the development of their Continuous Blood Glucose Monitor (CBGM). Dr. Hirsh, an experienced cardiac electrophysiologist from Harbin Clinical Cardiology Rome, brings extensive expertise in interventional cardiology procedures.
The appointment strengthens Glucotrack's clinical leadership as they advance their long-term implantable CBGM system, which is designed for up to three years of continuous monitoring. Unlike traditional monitors that measure glucose from interstitial fluid, Glucotrack's device measures directly from blood, aiming to provide real-time readings without lag time. The system features a unique intravascular placement approach and requires no wearable component.
Glucotrack (NASDAQ:GCTK) ha nominato Dr. David S. Hirsh come Direttore Medico di Cardiologia per supportare lo sviluppo del loro Monitor Continuo della Glicemia (CBGM). Il Dr. Hirsh, esperto elettrofisiologo cardiaco presso Harbin Clinical Cardiology Rome, apporta una vasta esperienza nelle procedure di cardiologia interventistica.
Questa nomina rafforza la leadership clinica di Glucotrack nel progresso del loro sistema CBGM impiantabile a lungo termine, progettato per un monitoraggio continuo fino a tre anni. A differenza dei monitor tradizionali che misurano il glucosio dal fluido interstiziale, il dispositivo di Glucotrack misura direttamente dal sangue, con l'obiettivo di fornire letture in tempo reale senza ritardi. Il sistema presenta un approccio unico di posizionamento intravascolare e non richiede componenti indossabili.
Glucotrack (NASDAQ:GCTK) ha nombrado al Dr. David S. Hirsh como Director Médico de Cardiología para apoyar el desarrollo de su Monitor Continuo de Glucosa en Sangre (CBGM). El Dr. Hirsh, cardiólogo electrofisiólogo experimentado de Harbin Clinical Cardiology Rome, aporta una amplia experiencia en procedimientos de cardiología intervencionista.
Este nombramiento fortalece el liderazgo clínico de Glucotrack mientras avanzan en su sistema CBGM implantable a largo plazo, diseñado para hasta tres años de monitoreo continuo. A diferencia de los monitores tradicionales que miden la glucosa en el fluido intersticial, el dispositivo de Glucotrack mide directamente en sangre, buscando proporcionar lecturas en tiempo real sin retrasos. El sistema cuenta con un enfoque único de colocación intravascular y no requiere componentes portátiles.
Glucotrack (NASDAQ:GCTK)는 지속 혈당 모니터링기(CBGM) 개발을 지원하기 위해 Dr. David S. Hirsh를 심장학 의료 책임자로 임명했습니다. Harbin Clinical Cardiology Rome의 경험 많은 심장 전기생리학자인 Hirsh 박사는 중재적 심장학 절차에 대한 풍부한 전문 지식을 보유하고 있습니다.
이번 임명은 최대 3년간 연속 모니터링이 가능한 장기 이식형 CBGM 시스템 개발을 진전시키는 Glucotrack의 임상 리더십을 강화합니다. 기존의 간질액에서 포도당을 측정하는 모니터와 달리, Glucotrack의 장치는 혈액에서 직접 측정하여 지연 시간 없이 실시간 수치를 제공합니다. 이 시스템은 독특한 혈관 내 삽입 방식을 특징으로 하며 착용형 부품이 필요하지 않습니다.
Glucotrack (NASDAQ:GCTK) a nommé Dr. David S. Hirsh en tant que Directeur Médical de Cardiologie pour soutenir le développement de leur Moniteur Continu de Glucose Sanguine (CBGM). Le Dr Hirsh, un électrophysiologiste cardiaque expérimenté de Harbin Clinical Cardiology Rome, apporte une expertise approfondie dans les procédures de cardiologie interventionnelle.
Cette nomination renforce le leadership clinique de Glucotrack alors qu'ils font progresser leur système CBGM implantable à long terme, conçu pour une surveillance continue jusqu'à trois ans. Contrairement aux moniteurs traditionnels qui mesurent la glycémie dans le liquide interstitiel, l'appareil de Glucotrack mesure directement dans le sang, visant à fournir des lectures en temps réel sans délai. Le système présente une approche unique de placement intravasculaire et ne nécessite aucun composant portable.
Glucotrack (NASDAQ:GCTK) hat Dr. David S. Hirsh zum Medizinischen Leiter der Kardiologie ernannt, um die Entwicklung ihres kontinuierlichen Blutzuckermonitors (CBGM) zu unterstützen. Dr. Hirsh, ein erfahrener kardialer Elektrophysiologe von Harbin Clinical Cardiology Rome, bringt umfangreiche Expertise in interventionellen Kardiologie-Verfahren mit.
Die Ernennung stärkt die klinische Führung von Glucotrack, während sie ihr langzeitimplantierbares CBGM-System vorantreiben, das für bis zu drei Jahre kontinuierliche Überwachung ausgelegt ist. Im Gegensatz zu herkömmlichen Monitoren, die den Glukosewert aus interstitieller Flüssigkeit messen, misst das Gerät von Glucotrack direkt aus dem Blut und zielt darauf ab, Echtzeitwerte ohne Verzögerung zu liefern. Das System verfügt über einen einzigartigen intravaskulären Platzierungsansatz und benötigt keine tragbaren Komponenten.
- Appointment of experienced cardiac specialist Dr. Hirsh strengthens clinical leadership
- CBGM technology offers up to 3 years of continuous monitoring without wearable components
- Direct blood glucose measurement eliminates lag time present in traditional monitoring systems
- Device leverages proven cardiovascular implantation techniques
- None.
Insights
Glucotrack strengthens clinical development with strategic cardiology hire for its novel implantable glucose monitor currently in clinical trials.
Glucotrack's appointment of Dr. David Hirsh as Medical Director for Cardiology represents a strategic enhancement to their clinical development team as they advance their innovative Continuous Blood Glucose Monitor (CBGM). This isn't merely an administrative hire - it's a calculated move to strengthen the company's clinical expertise in a critical developmental phase.
The company's technology approach is particularly noteworthy. Unlike traditional continuous glucose monitors that measure glucose in interstitial fluid, Glucotrack's CBGM measures glucose directly from blood through an intravascular implant designed to last up to three years with no external wearable component. This approach aims to eliminate the lag time inherent in current CGM technologies while providing a more convenient monitoring solution.
Dr. Hirsh's background in interventional cardiology and electrophysiology is directly relevant to Glucotrack's technological approach. The CBGM's intravascular placement leverages established cardiovascular implantation techniques - a domain where Dr. Hirsh's expertise will be valuable for site selection, physician training, and protocol compliance during clinical trials.
The company is currently conducting an OUS (outside US) early feasibility study and preparing for a US pilot study - crucial developmental milestones that will benefit from specialized cardiovascular oversight. Dr. Hirsh's role appears focused on both advancing these clinical trials and developing the educational framework necessary for eventual commercial deployment.
If successful, Glucotrack's approach could represent a significant advancement in diabetes care technology, offering a less intrusive, maintenance-free alternative to current glucose monitoring systems.
Experienced cardiac electrophysiologist joins Glucotrack’s growing clinical advisory team as the Company advances its long-term CBGM through critical clinical milestones
RUTHERFORD, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that David S. Hirsh, MD, has joined the Company’s clinical advisory team as Medical Director – Cardiology, providing strategic leadership for clinical and educational initiatives for the Continuous Blood Glucose Monitor (CBGM).
“We are delighted to welcome Dr. Hirsh to the Company in this pivotal role supporting our novel clinical development program,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “Dr. Hirsh's expertise in interventional cardiology procedures directly supports our CBGM's unique intravascular placement—an approach that builds on proven cardiovascular design concepts and outpatient procedures to deliver accurate, real-time glucose readings. As we advance through our clinical trials, including our long-term OUS early feasibility study and upcoming US pilot study, his clinical oversight will be valuable for appropriate site selection, physician education and protocol compliance.”
Dr. Hirsh brings extensive cardiology and electrophysiology experience. Since early 2025, he has been a cardiac electrophysiologist at Harbin Clinical Cardiology Rome. Prior to joining Harbin Clinical, Dr. Hirsh served as an Associate Professor of Medicine in the Division of Cardiology at Emory University School of Medicine, as the Director of Clinical Cardiac Electrophysiology at Grady Memorial Hospital, where he started the electrophysiology laboratory at Atlanta’s large public hospital, and as clinical cardiac electrophysiologist at the Atlanta VA Medical Center. He obtained his medical degree from Albert Einstein College of Medicine at Yeshiva University and completed his residency and fellowships at the New York University Medical Center where he was appointed the Chief Fellow in Internal Medicine, Cardiovascular Disease, and Clinical Cardiac Electrophysiology during his training.
"I am honored to join Glucotrack during this exciting phase of clinical development,” said Dr. Hirsh. “Glucotrack's approach of using proven cardiovascular implantation techniques for continuous blood glucose monitoring represents a breakthrough in diabetes care and I look forward to applying my cardiology expertise to help advance this technology through clinical trials and toward commercialization.”
The addition of Dr. Hirsh strengthens Glucotrack's clinical leadership team as the Company progresses through multiple clinical milestones. His role will also be critical for developing education and training programs for cardiac interventionalists and for engaging with the endocrinology community on coordinated clinical care for people living with diabetes.
Glucotrack’s CBGM is a long-term implantable system with no wearable component, designed for up to three years of continuous, accurate blood glucose monitoring, offering a more convenient and less intrusive glucose monitoring solution. The CBGM measures glucose directly from blood, unlike traditional continuous glucose monitoring systems which measure glucose from interstitial fluid. Thus, it aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements.
About Glucotrack, Inc.
Glucotrack, Inc. (Nasdaq: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
FAQ
Who is Dr. David S. Hirsh and what is his role at Glucotrack (GCTK)?
What makes Glucotrack's (GCTK) CBGM different from traditional glucose monitors?
What is Dr. Hirsh's background and experience?
What are the upcoming clinical trials for Glucotrack's (GCTK) CBGM?
How will Dr. Hirsh contribute to Glucotrack's (GCTK) development?
